---
title: "eSMARTER trial: Digital versus Clinician-Mediated Return of APOE and pTau-217 Results"
id: "medrxiv-8-returning-apoe-and-ptau-217-results-the-esmarter-randomized-noninferiority"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-returning-apoe-and-ptau-217-results-the-esmarter-randomized-noninferiority"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1?rss=1"
published_at: "2026-09-01T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# eSMARTER trial: Digital versus Clinician-Mediated Return of APOE and pTau-217 Results
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-returning-apoe-and-ptau-217-results-the-esmarter-randomized-noninferiority
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1?rss=1)
- **Published At:** 2026-09-01T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The eSMARTER trial compared a patient-centered **digital platform** to clinician-mediated telehealth for returning **APOE** genotype results and optional plasma **pTau-217** results in older adults. - This was a randomized noninferiority trial conducted fully remotely across the contiguous United States with enrollment Oct 2024–Feb 2025 and follow-up completed Nov 2025. - Eligible participants were aged 60–80, previously genotyped for **APOE** via GeneMatch without disclosure, passed psychological screening, had internet access, and spoke English. - 674 eligible persons provided demographics; 651 were randomized 2:1 (digital n=435, clinician-mediated n=216) and completed APOE disclosure. APOE status breakdown: 66 (10%) homozygotes, 377 (58%) heterozygotes, 208 (32%) non-carriers. - Primary outcomes assessed at 1–7 days after APOE disclosure were changes in anxiety (PROMIS Anxiety), disease-specific distress, and AD-related knowledge, evaluated within pre-specified noninferiority margins. - Results showed the digital platform met noninferiority compared with clinician-mediated disclosure on AD-related knowledge, anxiety, and disease-specific distress at 1–7 days post-disclosure. - After 6 months, participants could opt to receive **pTau-217** results via the same randomized modality; 500 participants completed optional pTau-217 disclosure and no significant between-group differences were observed following pTau-217 disclosure. - 604 participants completed the overall study. Baseline characteristics were balanced across randomized groups. - The trial was IRB-approved (Advarra #Pro00064250), registered (Clinical Trial NCT06459583), and deidentified data are available on request subject to a Data Use Agreement. - Multiple authors reported funding from NIA and other entities; several disclosed relationships with industry, including involvement with assays and companies related to plasma **pTau-217** testing; specific competing interests are reported in the source.
## Clinical Analysis & Structured Key Points
Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial | medRxiv Skip to main content Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial View ORCID Profile Jessica B Langbaum , Claire M Erickson , Carolyn Langlois , Elisabeth M Wood , Brian L Egleston , Kristin Harkins , Rajia Mim , Samantha John , Camille Brown , Sarah Brown , Sarah Howe , Cara Cacioppo , Laura Eppelmann , Jessica Enos , Hayley Salata , Diana DeSantiago , Emily A Largent , View ORCID Profile Eric M Reiman , Marisa N Denkinger , Nicholas J Ashton , J Scott Roberts , Jason Karlawish , Angela R Bradbury doi: https://doi.org/10.64898/2026.08.27.26361535 Jessica B Langbaum 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jessica B Langbaum For correspondence: jessica.langbaum{at}bannerhealth.com Claire M Erickson 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carolyn Langlois 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elisabeth M Wood 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Brian L Egleston 3 Fox Chase Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kristin Harkins 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rajia Mim 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Samantha John 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Camille Brown 4 Dignity Health St Joseph's Hospital and Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sarah Brown 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sarah Howe 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cara Cacioppo 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Laura Eppelmann 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jessica Enos 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hayley Salata 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Diana DeSantiago 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Emily A Largent 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eric M Reiman 1 Banner Alzheimer's Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eric M Reiman Marisa N Denkinger 5 Banner Sun Health Research Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nicholas J Ashton 5 Banner Sun Health Research Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site J Scott Roberts 6 University of Michigan Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jason Karlawish 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Angela R Bradbury 2 University of Pennsylvania; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Importance: Patients are increasingly learning Alzheimers disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient understanding and psychological well-being. Objective: To determine whether a patient-centered digital platform is comparable to clinician-mediated telehealth sessions for returning APOE and plasma pTau-217 results on outcomes of knowledge and psychological well-being. Design: The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a patient-centered digital platform compared to clinician-mediated disclosure of APOE genotype and optional pTau-217 disclosure. Setting: Decentralized, fully remote trial enrolled participants in the contiguous United States (U.S.) between October 2024 and February 2025, with follow-up completed in November 2025. Participants: Eligible participants were aged 60-80 and had previously undergone APOE genotyping (without disclosure) via the GeneMatch program, passed psychological screening, had internet access, and were English-speaking. Interventions: Participants were randomized, 2:1, to the eSMARTER digital platform or clinician-mediated disclosure of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional pTau-217 disclosure via the same randomized modality. Main Outcomes and Measures: Primary outcomes at 1-7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori non-inferiority margins. Results: 674 persons (mean [SD] age 68 [4.7] years; 451 [67%] female; mean [SD] telephone MoCA=19 [2]) were eligible and provided demographic information. 651 participants were randomized to clinician-mediated (n=216) or digital disclosure (n=435) and completed APOE disclosure (66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, 208 [32%] non-carriers). 604 participants completed the study; 500 completed optional pTau-217 disclosure. Baseline characteristics were balanced across groups. At 1-7 days following APOE disclosure, scores on AD-related knowledge, PROMIS Anxiety, and disease-specific distress measures met non-inferiority. Conclusions and Relevance: Disclosure of APOE genotype by the eSMARTER digital platform is non-inferior to clinician-mediated telehealth disclosure. No significant between group differences were found following disclosure of pTau-217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results. Competing Interest Statement Jessica Langbaum reported receiving grants from the National Institute on Aging (NIA) and the Arizona Department of Health Services via the Arizona Alzheimers Consortium during the conduct of this study. Banner Health received institutional grants or contracts from Eli Lilly. She received personal fees from Premiere Inc. outside the submitted work. Eric Reiman reported receiving grants from the National Institute on Aging (NIA) and the Arizona Department of Health Services via the Arizona Alzheimers Consortium during the conduct of this study. Banner Health received institutional grants or contracts from Eli Lilly. He received personal fees from Alzheon. Beren Therapeutics. Cognition Therapeutics. Denali Therapeutics. Enigma Diagnostics. New Amsterdam Therapeutics. Retromer Therapeutics. Vaxxinity. He is a co-founder and advisor to ALZPath maker of a pTau-217 capture antibody that has been licensed to for plasma pTau-217 assays on several immunoassay platforms, including the Roche platform used in this study. Scott Roberts reported receiving grants from the National Institutes of Health and the Alzheimers Association during the conduct of this study. Jason Karlawish reported receiving grants from the National Institute on Aging (NIA) and the Pennsylvania Department of Public Health during the conduct of this study. He has received consulting fees from Darmiyan and serves on the board of directors for the Greenwall Foundation Emily Largent reported receiving grants from the National Institute on Aging (NIA) and the Greenwall Foundation during the conduct of this study. She received personal fees from Novartis outside the submitted work. Nicholas Ashton reported receiving grants from the National Institute on Aging (NIA) and the Arizona Department of Health Services via the Arizona Alzheimers Consortium during the conduct of this study. He serves on scientific advisory boards for Alamar Biosciences (ADDF initiative). Biogen. New Amsterdam Pharma. Bristol Myers Squibb. Abbott. He has received consultancy/speaker fees from Alamar Biosciences. Bioartic. Biogen. Eli Lilly. Neurogen Biomarking. Roche. Spear Bio. Quanterix and Vigil Neurosciences. Brian Egleston receives salary support paid to his employer from the National Institutes of Health. NASA. the Department of War. He also receives honoraria from American Journal Experts LLC for journal reviews. Angela Bradbury received research support from AstraZeneca for a separate trial evaluating digital interventions in cancer genetics (eREACH1). She is also founder of Lucidigene LLC. Claire Erickson, Carolyn Langlois, Elisabeth Wood, Kristin Harkins, Rajia Mim, Samantha John, Sarah Brown, Sarah Howe, Cara Cacioppo, Laura Eppelmann, Jessica Enos, Hayley Salata, Diana DeSantiago, and Marisa Denkinger have no relevant conflicts of interest to disclose. Clinical Trial NCT06459583 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The eSMARTER protocol was approved by an Advarra institutional review board (IRB) (#Pro00064250), and all participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Deidentified data are available. Requests for access to the study data can be submitted by emailing a description of your request to APIData{at}bannerhealth.com. A Data Use Agreement will need to be completed with Banner Health prior to transfer of data. Funder Information Declared National Institutes of Health , R01AG058468 , P30AG072980 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 01, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial Jessica B Langbaum , Claire M Erickson , Carolyn Langlois , Elisabeth M Wood , Brian L Egleston , Kristin Harkins , Rajia Mim , Samantha John , Camille Brown , Sarah Brown , Sarah Howe , Cara Cacioppo , Laura Eppelmann , Jessica Enos , Hayley Salata , Diana DeSantiago , Emily A Largent , Eric M Reiman , Marisa N Denkinger , Nicholas J Ashton , J Scott Roberts , Jason Karlawish , Angela R Bradbury medRxiv 2026.08.27.26361535; doi: https://doi.org/10.64898/2026.08.27.26361535 Share This Article: Copy Citation Tools Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial Jessica B Langbaum , Claire M Erickson , Carolyn Langlois , Elisabeth M Wood , Brian L Egleston , Kristin Harkins , Rajia Mim , Samantha John , Camille Brown , Sarah Brown , Sarah Howe , Cara Cacioppo , Laura Eppelmann , Jessica Enos , Hayley Salata , Diana DeSantiago , Emily A Largent , Eric M Reiman , Marisa N Denkinger , Nicholas J Ashton , J Scott Roberts , Jason Karlawish , Angela R Bradbury medRxiv 2026.08.27.26361535; doi: https://doi.org/10.64898/2026.08.27.26361535 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (895) Anesthesia (326) Cardiovascular Medicine (4768) Dentistry and Oral Medicine (474) Dermatology (406) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1614) Epidemiology (15832) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6982) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4980) Health Policy (1426) Health Systems and Quality Improvement (1735) Hematology (581) HIV/AIDS (1334) Infectious Diseases (except HIV/AIDS) (16243) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (720) Neurology (7191) Nursing (363) Nutrition (1074) Obstetrics and Gynecology (1231) Occupational and Environmental Health (1001) Oncology (3572) Ophthalmology (1036) Orthopedics (393) Otolaryngology (446) Pain Medicine (465) Palliative Medicine (139) Pathology (702) Pediatrics (1772) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5830) Public and Global Health (9688) Radiology and Imaging (2386) Rehabilitation Medicine and Physical Therapy (1432) Respiratory Medicine (1239) Rheumatology (633) Sexual and Reproductive Health (766) Sports Medicine (576) Surgery (766) Toxicology (107) Transplantation (302) Urology (286)
## Related Clinical Research

- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)
- [Hormone replacement therapy timing and menopause type linked to dementia risk in large UK study](https://medichelpline.com/clinical-feed/medical-news-today-1-menopause-type-and-hrt-timing-influence-dementia-risk-large-study-suggests.md)
- [DSM-6 should include algorithmic and social media exposure in eating disorder assessments](https://medichelpline.com/clinical-feed/stat-news-2-opinion-the-next-dsm-should-address-the-algorithm-s-role-in-eating-disorders.md)
- [Independent review: Disruptions, not censorship, at ADA’s June Scientific Sessions](https://medichelpline.com/clinical-feed/stat-news-1-opinion-diabetes-association-ceo-what-an-independent-review-says-happened-at.md)
- [Sex Differences in Cognitive Impairment and Dementia After Incident Atrial Fibrillation and the Im](https://medichelpline.com/clinical-feed/medrxiv-7-a-population-based-study-of-sex-differences-in-cognitive-impairment-and.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.